Plate Nº 86 · recorded October 13, 2026
Health & Medicine ResearchReported finding
How Excess Salt May Trigger Fatty Liver Disease in Lean Patients
Duke-NUS researchers report the first diet-induced mouse model of lean MASH, linking high dietary salt to liver inflammation independent of obesity.
By Priya Raman3 min read554 words
In brief
- Up to 40% of people in some westernized Asian populations carry MASH, the severe inflammatory form of fatty liver disease.
- The study was published in Molecular Metabolism in 2026, DOI: 10.1016/j.molmet.2026.102417.
- The Duke-NUS team created the world's first diet-induced mouse model of lean MASH.
- High dietary salt increased hepatic fat breakdown and activated inflammatory immune cells in the mouse liver.
- Cardiovascular disease is a leading cause of death among MASH patients.
Up to 40% of people in some westernized Asian populations carry MASH, the severe inflammatory form of fatty liver disease — and a growing share of those patients are not overweight. Researchers at Duke-NUS Medical School now point to one possible driver: excess dietary salt can reshape liver metabolism and trigger inflammation even without obesity.
The findings appear in a study published in Molecular Metabolism. The work introduces what the team describes as the world's first diet-induced mouse model of lean MASH (metabolic dysfunction-associated steatohepatitis), the progressive liver disease marked by persistent inflammation and scarring that can advance to cirrhosis, liver failure, or liver cell cancer.
"We can now begin to ask whether the mechanisms driving liver injury in lean MASH also affect the heart," said Derek John Hausenloy, a professor in the Cardiovascular & Metabolic Disorders Signature Research Programme at Duke-NUS and one of the study's authors.
How does lean MASH differ from the obesity-linked form?
Lean MASH refers to metabolic dysfunction-associated steatohepatitis that develops in people with a normal body mass index. The Duke-NUS model reproduces key clinical features seen in such patients: relatively low liver fat, paired with severe inflammation and scarring. This pattern tracks with observations that lean patients may carry less liver fat yet face a higher risk of serious complications and death.
Until now, no suitable laboratory models existed for the condition.
What did the high-salt diet do to the liver?
Feeding mice a MASH-inducing diet supplemented with high salt altered how the organ processes fat. The liver increased fat breakdown while activating immune cells that drive inflammation. The supplement also reshaped the urea cycle — the liver's nitrogen-disposal pathway — and a protein modification called EIF5A hypusination.
Observed changes include:
- Increased hepatic fat breakdown
- Activation of liver inflammatory immune cells
- Upregulated urea cycle activity
- Hypusination of EIF5A, a protein involved in cell growth
Why does this matter for treatment?
Lead author Dr. Zhou Jin, a principal research scientist at Duke-NUS and a Gilead Research Scholar, said: "Our findings suggest that lean MASH is not simply the same disease occurring in a thinner person. The biology appears to be different. While obesity-associated MASH is closely linked to excess fat accumulation, our model shows that high dietary salt can alter liver metabolism and activate inflammatory pathways even without obesity."
The distinction, she argued, matters for drug development: therapies designed for obesity-associated MASH may not address what drives disease in lean patients.
What is the link to cardiovascular disease?
Cardiovascular disease remains the leading cause of death among MASH patients. Hausenloy framed the new model as a tool for studying lean MASH as a whole-body disease rather than an isolated liver condition. The team includes collaborators from the National Heart Centre Singapore, Duke University School of Medicine, and University College London.
What comes next?
The team plans to use the model to identify early diagnostic biomarkers and to test compounds that block the salt-induced inflammatory pathways identified in the study. Professor Lok Shee-Mei, vice dean of research at Duke-NUS, called the work "an important foundation for developing diagnostics and treatments that reflect the biology of the individual patients."
The Duke-NUS group will now pursue targeted drug testing and early markers of lean MASH.
via Medical Xpress (Source)
More from Priya Raman
Show full bio
Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.
222 articles
Nearby plates
- Protective Enzyme UBE2N May Keep Fatty Liver Disease From Worsening
- Phase 3 trial tests survodutide for obesity-linked fatty liver disease
- High IgA Levels Identify a High-Risk Subtype of Fatty Liver Disease
- Late-Night Eating Linked to 20–30% Higher Liver Disease Risk
- Keto Diet Raises Small-Intestine Tumor Risk in MIT Mouse Study